

TRANSGENOMIC INC  
Form 8-K  
January 14, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January 13, 2015**

**Transgenomic, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**                                    **000-30975 91-1789357**  
(State or Other Jurisdiction of (Commission (IRS Employer  
Incorporation)                                    File Number) Identification No.)

**12325 Emmet Street, Omaha, NE 68164**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(402) 452-5400**

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On January 13, 2015, the Chief Executive Officer of Transgenomic, Inc., a Delaware corporation (the “Company”), presented at the OneMed Conference in San Francisco, California regarding the Company’s Multiplexed ICE COLD-PCR™ (“MX-ICP”) product line and its product and commercial roadmap for 2015. A copy of the investor presentation is posted on the “Investor Relations” section of the Company’s website at [www.transgenomic.com/investor-relations](http://www.transgenomic.com/investor-relations). The investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished under Item 7.01 (Regulation FD Disclosure) of Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01. Other Events.**

On January 14, 2015, the Company issued a press release announcing that the commercial launch of its MX-ICP product line is scheduled in the first quarter of 2015. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Transgenomic, Inc. Investor Presentation, dated January 2015.

99.2 Press Release, dated January 14, 2015, announcing the scheduled commercial launch of Transgenomic, Inc.’s Multiplexed ICE COLD-PCR™ product line in the first quarter of 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Transgenomic, Inc.**

By: /s/ Paul Kinnon  
Paul Kinnon  
President and Chief Executive Officer

Date: January 14, 2015